论文部分内容阅读
目的观察美托洛尔联合福辛普利治疗高血压伴有微量白蛋白尿患者的临床疗效。方法选择148例原发性高血压伴微量白蛋白尿患者,随机分为治疗组(74例,予以美托洛尔25mg/bid联合福辛普利10mg/qd)和对照组(74例,予以美托洛尔25mg/bid联合硝苯地平缓释片10mg/bid),治疗前后分别测血压及尿微量白蛋白值,并进行比较。结果两组药物均能明显降低血压及尿微量白蛋白(P<0.05),而治疗组降低尿微量白蛋白疗效优于对照组(P<0.05)。结论美托洛尔联合福辛普利降压效果显著,且具有较好的降低高血压患者的尿微量白蛋白,具有保护肾脏的作用。
Objective To observe the clinical efficacy of metoprolol combined with fosinopril in patients with hypertension and microalbuminuria. Methods A total of 148 patients with essential hypertension and microalbuminuria were randomly divided into treatment group (74 cases, metoprolol 25mg / bid combined with fosinopril 10mg / qd) and control group (74 cases, Metoprolol 25mg / bid combined with nifedipine sustained-release tablets 10mg / bid), before and after treatment were measured blood pressure and urinary albumin values, and compared. Results Both drugs significantly reduced blood pressure and urinary microalbuminuria (P <0.05), while the therapeutic effect of reducing urinary albumin in the treatment group was better than that of the control group (P <0.05). Conclusion Metoprolol combined with fosinopril has significant antihypertensive effect, and has a good reduction of microalbuminuria in patients with hypertension, with the role of protecting the kidneys.